Drug facts
MoleculeMeloxicam
Generics already compete: 13 makers on the market. 28 A-rated products from 13 makers substitute at the counter.
Mobic was first approved by the FDA on 04/13/2000 under NDA 020938; the application holder is Boehringer Ingelheim Pharmaceuticals Inc. The Orange Book lists NDA 020938 as discontinued.
The latest NADAC for MELOXICAM 15 MG TABLET is $0.02 per unit (as of 10/28/2026).
Holder Boehringer Ingelheim Pharmaceuticals IncApplication NDA 020938Approved 04/13/2000
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No Mobic patent listed in the Orange Book Orange Book
- Later patents, other products
- Xifyrm 07/31/2041; Qamzova 07/19/2040; Anjeso 03/08/2039; Vivlodex 03/31/2035; Qmiiz ODT 08/31/2030 Orange Book
02Competition
- Generics
- 13 generic makers Orange Book
- First generic approved
- 07/19/2006 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Meloxicam profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $0.02 per unitMELOXICAM 15 MG TABLET, as of 10/28/2026 CMS NADAC
- Latest recall
- 01/26/2022Class II, Meloxicam, Cardinal Healthcare FDA enforcement
04Product
- Application holder
- Boehringer Ingelheim Pharmaceuticals Inc Orange Book
- Application
- NDA 020938 Orange Book
- First approved
- 04/13/2000 Orange Book
- Dosage forms
- capsule; solution; suspension; tablet
- Routes
- intravenous, oral
- Other brand names
- Qamzova
- Status
- NDA 020938 discontinued Orange Book
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.